Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)
PolyPid Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)
HC Wainwright & Co. : The PolyPid (PYPD.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
PolyPid Analyst Ratings
Buy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline Potential
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), PolyPid (PYPD) and Nyxoah (NYXH)
Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning
PolyPid (PYPD) Receives a Hold From Barclays
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Crinetics Pharmaceuticals (CRNX) and PolyPid (PYPD)
Barclays Maintains Equal-Weight on PolyPid, Raises Price Target to $10
PolyPid Analyst Ratings
HC Wainwright & Co. Initiates Coverage On PolyPid With Buy Rating, Announces Price Target of $16
PolyPid Analyst Ratings
Promising Clinical Trials and Innovative PLEX Technology Drive Analyst's Buy Rating for PolyPid Ltd.
Resilient PolyPid Maintains Buy Rating Despite Challenges: An Analysis of Ongoing Trials and Financial Adjustments
JMP Securities Keeps Their Buy Rating on PolyPid (PYPD)
JMP Securities Sticks to Its Buy Rating for PolyPid (PYPD)
No Data